HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Cautions Against Modeling TSCA Reforms After REACH

This article was originally published in The Rose Sheet

Executive Summary

While industry, NGOs, legislators and others agree that the 35-year-old Toxic Substances Control Act should be reformed, stakeholders disagree on whether to use the European Union's Registration, Evaluation, Authorization and Restriction of Chemicals as a guide.

You may also be interested in...



Draft CSIA Bill “Reproduces” TSCA, Endangers State Programs – Critics

Bipartisan bill proposed to update U.S. chemicals regulation – the Chemical Safety Improvement Act – “was written to suit the chemicals industry” and would actually be a step backward from the status quo under TSCA, the Environmental Working Group suggests. Other NGOs and legal experts voiced similar criticisms in letters to key Senate members.

Sen. Lautenberg Plans Toxic Substances Control Update Bill

Introducing a bill to modernize the 36-year-old Toxic Substances Control Act is a priority for Senator Frank Lautenberg in the 113th Congress. Senator David Vitter might introduce his own industry-backed bill to modernize the act.

Sen. Lautenberg Plans Toxic Substances Control Update Bill

Introducing a bill to modernize the 36-year-old Toxic Substances Control Act is a priority for Senator Frank Lautenberg in the 113th Congress. Senator David Vitter might introduce his own industry-backed bill to modernize the act.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017444

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel